Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue SUPPL. 242, 2010, Pages 73-78

  Cerdeira, Ana Sofia ^a,b   Karumanchi, S Ananth ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b Gulbenkian Program for Advanced Medical Education   (Portugal)

Author keywords

Angiogenic proteins; Diagnostic tests; Hypertension; Preeclampsia; Proteinuria

Indexed keywords

ANGIOGENIC PROTEIN; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER;

CLINICAL EVALUATION; CLINICAL FEATURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; GESTATIONAL AGE; HUMAN; MATERNAL HYPERTENSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL CHEMISTRY; FEMALE; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PREDICTION AND FORECASTING; PREGNANCY; PROTEINURIA; SENSITIVITY AND SPECIFICITY;

ANGIOGENIC PROTEINS; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROTEINURIA; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 77953169288     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.493400     Document Type: Review

References (41)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-7.
2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-99.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371:261-9.
4. Hofman PL, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, et al. Premature birth and later insulin resistance. N Engl J Med. 2004;351:2179-86.
5. Irving RJ, Belton NR, Elton RA, Walker BR. Adult cardiovascular risk factors in premature babies. Lancet. 2000;355:2135-6.
6. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-9. (Pubitemid 43865232)
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58.
8. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190:1541-7;
9. discussion 7-50.
10. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-91.
11. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
13. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-71.
14. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993;90:10705-9.
15. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267:19027-30.
16. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005;96:684-92.
17. Parikh SM, Karumanchi SA. Putting pressure on preeclampsia. Nat Med. 2008;14:810-2.
18. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004;50:1702-3.
19. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003;101:1266-74.
20. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89:770-5.
21. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol. 2001;184:1267-72.
22. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, et al. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005;293:77-85.
23. Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmaki E, Finne P, et al. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91:180-4.
24. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137-42.
25. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196:239, e1-6.
26. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21:279-87.
27. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244, e1-8.
28. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med. 2009;22:1021-38.
29. Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V. Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int. 2006;69:621-4.
30. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005 Mar; 192 (3):734-41.
31. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818-24.
32. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:175, e1-6.
33. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009 May; 53 (5):812-8.
34. Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension. 2009;53:747-8.
35. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197:28, e1-6.
36. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, et al. Automated assays for sVEGFR1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol. 2010;202:40, e1-7.
37. Shan HY, Rana S, Epstein FH, Stillman IE, Karumanchi SA, Williams ME. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis. 2008;51:1029-32.
38. Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol. 2006;108:338-44.
39. Signore C, Mills JL, Qian C, Yu KF, Rana S, Karumanchi SA, et al. Circulating soluble endoglin and placental abruption. Prenat Diagn. 2008;28:852-8.
40. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161, e1-e11.
41. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010 Epubmed EISSN: 1348-4214.